New England Research & Management’s Vertex Pharmaceuticals VRTX Stock Holding History

New England Research & Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	2,575 +975	+61%	+$432K	0.5%	65
2026 Q1	$714K	Buy	+1,600	New	+$746K	0.3%	86
2025 Q4	–	Sell	-1,535	Closed	-$601K	–	176
2025 Q3	$601K	Buy	1,535 +475	+45%	+$199K	0.28%	99
2025 Q2	$472K	Buy	+1,060	New	+$488K	0.22%	109
2024 Q4	–	Sell	-4,575	Closed	-$2.13M	–	181
2024 Q3	$2.13M	Buy	4,575 +1,840	+67%	+$884K	1%	32
2024 Q2	$1.28M	Sell	2,735 -100	-4%	-$43.4K	0.62%	60
2024 Q1	$1.19M	Buy	+2,835	New	+$1.2M	0.58%	58
2023 Q2	–	Sell	-2,475	Closed	-$780K	–	160
2023 Q1	$780K	Buy	2,475 +1,525	+161%	+$457K	0.46%	80
2022 Q4	$274K	Buy	+950	New	+$290K	0.16%	135
2019 Q4	–	Sell	-2,725	Closed	-$462K	–	161
2019 Q3	$462K	Buy	2,725 +375	+16%	+$66.3K	0.33%	106
2019 Q2	$431K	Buy	2,350 +1,100	+88%	+$192K	0.29%	113
2019 Q1	$230K	Buy	+1,250	New	+$231K	0.16%	154

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

SMDAM

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return

New England Research & Management's VRTX Position: Q2 2026 in Review

New England Research & Management increased its Vertex Pharmaceuticals (VRTX) stake by 61% in Q2 2026, buying an estimated $432K and bringing the position to 2,575 shares worth $1.28M. The position accounts for 0.5% of the portfolio, ranked #65.

New England Research & Management first reported a position in VRTX in Q1 2019 and has held it in 12 quarters since. The position peaked at $2.13M in Q3 2024. 338 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

New England Research & Management held 2,575 shares of Vertex Pharmaceuticals worth $1.28M as of Q2 2026.
New England Research & Management bought 975 Vertex Pharmaceuticals shares in Q2 2026, an estimated $432K.
Vertex Pharmaceuticals made up 0.5% of New England Research & Management's portfolio in Q2 2026, its #65 holding.
New England Research & Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 12 quarters since.
New England Research & Management's Vertex Pharmaceuticals position peaked at $2.13M in Q3 2024.
338 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.